Analysen | Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
 Sie befinden sich in - Home - Canakinumab (L04AC08)
L04AC08 - CanakinumabATC-DDD Version 2016. Source: WHO
L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L04 - Immunosuppressants

Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.

L04A - Immunosuppressants

This group comprises immunosuppressants excl. corticosteroids.

The DDDs are mainly based on prophylaxis of allograft transplant rejection.
The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.
The DDD for efalizumab is based on the treatment of plaque psoriasis.
The DDDs for etanercept, infliximab, leflunomide, anakinra and adalimumab are based on the treatment of rheumatoid arthritis.
The DDD for thalidomide is based on the treatment of erythema nodosum leprosum.
The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.

L04AC - Interleukin Inhibitors

Interleukin inhibitors used in asthma are classified in R03DX.

L04AC08 - Canakinumab
2.7 mgP 
LGPL2017, Commit-ID
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home